Then, PCSK9 inhibition might enhance CD8+ T‐cell antitumor activity, which is a promising cancer immunotherapy target.[52] Additionally, PCSK9 activated the KRAS/MEK/ERK pathway by inducing cholesterol and geranylgeranyl pyrophosphate (GGPP) biosynthesis, through its binding with LDLR, leading to the dysregulation of cholesterol homeostasis, in APC/KRAS‐mutant colorectal cancer.[53] Overall, augmenting PCSK9 expression has been shown to enhance both tumor growth and metastasis. Here, KRAS is linked to colorectal cancer.